Aligos Therapeutics (ALGS)
Market Price (8/9/2026): $5.7 | Market Cap: $59.5 MilSector: Health Care | Industry: Biotechnology
Aligos Therapeutics (ALGS)
Market Price (8/9/2026): $5.7Market Cap: $59.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 893% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -89% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -147% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -251% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -299%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -300% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -135% Key risksALGS key risks include [1] its heavy dependence on the success of unproven, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -46% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 893% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -89% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -99%, 3Y Excs Rtn is -147% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -79 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -251% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -299%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -300% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -135% |
| Key risksALGS key risks include [1] its heavy dependence on the success of unproven, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Aligos Therapeutics (ALGS) stock has lost about 5% since 4/30/2026 because of the following key factors:
1. Analyst Price Target Revision. On May 21, 2026, an analyst price target for Aligos Therapeutics was decreased by 15% to US$58.17, indicating a downward adjustment in future valuation expectations.
2. Extended Timeline for Key Clinical Trial Data. Despite the completion of enrollment in the Phase 2 B-SUPREME study for pevifoscorvir sodium for chronic HBV infection, topline safety and efficacy data are not anticipated until late fiscal Q3 2027. This extended waiting period for significant clinical trial results can contribute to investor uncertainty and a lack of immediate catalysts for the clinical-stage biotechnology company.
Show more
Aligos Therapeutics (ALGS) stock has lost about 5% since 4/30/2026 because of the following key factors:
1. Analyst Price Target Revision. On May 21, 2026, an analyst price target for Aligos Therapeutics was decreased by 15% to US$58.17, indicating a downward adjustment in future valuation expectations.
2. Extended Timeline for Key Clinical Trial Data. Despite the completion of enrollment in the Phase 2 B-SUPREME study for pevifoscorvir sodium for chronic HBV infection, topline safety and efficacy data are not anticipated until late fiscal Q3 2027. This extended waiting period for significant clinical trial results can contribute to investor uncertainty and a lack of immediate catalysts for the clinical-stage biotechnology company.
3. Cash Runway and Increased Research and Development Expenses. Aligos Therapeutics reported a decrease in cash, cash equivalents, and investments from $77.8 million as of December 31, 2025, to $54.9 million as of March 31, 2026 (the end of fiscal Q1 2026). While an exclusive license deal secured an upfront payment of $25 million in July 2026, extending the cash runway into fiscal Q4 2026, the company's research and development expenses significantly increased to $23.4 million in fiscal Q1 2026, compared to $14.5 million in fiscal Q1 2025, reflecting continued substantial cash utilization for clinical trials.
Show less
Stock Movement Drivers
Fundamental Drivers
The -6.7% change in ALGS stock from 4/30/2026 to 8/8/2026 was primarily driven by a -93.5% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.99 | 5.59 | -6.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 32 | 1341.8% |
| P/S Multiple | 28.5 | 1.8 | -93.5% |
| Shares Outstanding (Mil) | 10 | 10 | -0.4% |
| Cumulative Contribution | -6.7% |
Market Drivers
4/30/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| ALGS | -6.7% | |
| Market (SPY) | 7.6% | 25.0% |
| Sector (XLV) | 13.5% | 7.6% |
Fundamental Drivers
The -30.7% change in ALGS stock from 1/31/2026 to 8/8/2026 was primarily driven by a -94.2% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.07 | 5.59 | -30.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 32 | 1091.2% |
| P/S Multiple | 31.6 | 1.8 | -94.2% |
| Shares Outstanding (Mil) | 10 | 10 | -0.6% |
| Cumulative Contribution | -30.7% |
Market Drivers
1/31/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| ALGS | -30.7% | |
| Market (SPY) | 12.1% | 30.0% |
| Sector (XLV) | 7.5% | 15.4% |
Fundamental Drivers
The -23.2% change in ALGS stock from 7/31/2025 to 8/8/2026 was primarily driven by a -90.1% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.28 | 5.59 | -23.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 32 | 863.9% |
| P/S Multiple | 18.7 | 1.8 | -90.1% |
| Shares Outstanding (Mil) | 8 | 10 | -19.4% |
| Cumulative Contribution | -23.2% |
Market Drivers
7/31/2025 to 8/8/2026| Return | Correlation | |
|---|---|---|
| ALGS | -23.2% | |
| Market (SPY) | 23.4% | 20.4% |
| Sector (XLV) | 28.7% | 18.9% |
Fundamental Drivers
The -74.9% change in ALGS stock from 7/31/2023 to 8/8/2026 was primarily driven by a -83.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.25 | 5.59 | -74.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 32 | 124.2% |
| P/S Multiple | 2.7 | 1.8 | -31.9% |
| Shares Outstanding (Mil) | 2 | 10 | -83.5% |
| Cumulative Contribution | -74.9% |
Market Drivers
7/31/2023 to 8/8/2026| Return | Correlation | |
|---|---|---|
| ALGS | -74.9% | |
| Market (SPY) | 74.9% | 27.4% |
| Sector (XLV) | 29.3% | 16.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALGS Return | -57% | -92% | -30% | 140% | -77% | -41% | -99% |
| Peers Return | -14% | 71% | 17% | 20% | 98% | -2% | 298% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| ALGS Win Rate | 50% | 25% | 25% | 50% | 33% | 38% | |
| Peers Win Rate | 45% | 45% | 40% | 48% | 57% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ALGS Max Drawdown | -67% | -93% | -73% | -76% | -91% | -61% | |
| Peers Max Drawdown | -41% | -41% | -41% | -42% | -35% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDGL, GILD, IONS, ARWR, VKTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)
How Low Can It Go
| Event | ALGS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.3% | -7.8% |
| % Gain to Breakeven | 14.0% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.8% | -9.5% |
| % Gain to Breakeven | 66.0% | 10.5% |
| Time to Breakeven | 78 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 73.9% | 7.1% |
| Time to Breakeven | 629 days | 31 days |
In The Past
Aligos Therapeutics's stock fell -12.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 14.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ALGS | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.8% | -9.5% |
| % Gain to Breakeven | 66.0% | 10.5% |
| Time to Breakeven | 78 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 73.9% | 7.1% |
| Time to Breakeven | 629 days | 31 days |
In The Past
Aligos Therapeutics's stock fell -12.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 14.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aligos Therapeutics (ALGS)
Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company focused on developing novel treatments for significant unmet medical needs within viral and liver diseases. Headquartered in South San Francisco, California, the company's research and development efforts are primarily directed toward creating innovative therapies for chronic conditions such as chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH).
The company's pipeline includes several promising drug candidates targeting chronic hepatitis B, with lead programs like ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer currently in Phase Ib clinical trials, and ALG-000184, a capsid assembly modulator in Phase I. Aligos is also developing other approaches for CHB, including ALG-020572 (an antisense oligonucleotide) and siRNA candidates. For liver diseases, Aligos is advancing ALG-055009, a small molecule THR-ß agonist, which is in Phase 1a/1b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH).
Aligos Therapeutics aims to serve patients globally who suffer from these chronic viral and liver diseases, specifically CHB and NASH. The company's business model incorporates both internal drug discovery and strategic collaborations, demonstrated through agreements with partners like Luxna Biotech, Emory University, and Merck, to leverage diverse technologies and expertise in the development and potential commercialization of its therapeutic programs.
AI Analysis | Feedback
Here are 1-2 brief analogies for Aligos Therapeutics:
An early-stage Gilead Sciences, specializing in developing new treatments for chronic hepatitis B and fatty liver disease.
A biotech startup focused on discovering breakthrough drugs for liver and viral diseases, much like a young Vertex Pharmaceuticals before its major successes in specific disease areas.
AI Analysis | Feedback
- ALG-010133: An oligonucleotide polymer designed to inhibit s-antigen transport for chronic hepatitis B.
- ALG-000184: A capsid assembly modulator in development for chronic hepatitis B.
- ALG-020572: An antisense oligonucleotide aimed at preventing HBsAg translation and secretion.
- ALG-055009: A small molecule THR-ß agonist targeting non-alcoholic steatohepatitis (NASH).
- ALG-125755: An siRNA drug candidate developed to inhibit HBsAg release.
- ALG-125097 and ALG-125819: Drug candidates designed to potently inhibit HBsAg release from HBV-infected cells.
AI Analysis | Feedback
Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics. As such, it does not currently have commercial products on the market sold to individuals or traditional customers.
Instead, its major "customers" or revenue sources come from strategic collaborations and licensing agreements with other companies and institutions that provide funding, research support, and rights for future commercialization of its drug candidates and technologies. Based on the provided description, these include:
- Luxna Biotech Co., Ltd. (Private company)
- Emory University (Academic institution)
- Katholieke Universiteit Leuven (Academic institution)
- Merck (Public company, symbol:
MRK) - *Correction: Merck & Co., Inc. symbol is MRK.*
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
The key risks to Aligos Therapeutics (ALGS) are primarily related to its financial viability, the inherent challenges of drug development, and intense competition in its target therapeutic areas.
-
Financial Health and Going Concern Risk: Aligos Therapeutics faces significant financial challenges, with reported negative operating and net margins and a low cash runway. Management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional financing, as existing funds are expected to last only into the third quarter of 2026. This indicates a critical need for further capital to sustain operations and ongoing drug development programs.
-
Clinical Development and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Aligos' future success is highly dependent on the successful outcome of its drug candidates in clinical trials and their ability to gain regulatory approval. The company's lead candidates, such as ALG-010133, ALG-000184 (pevifoscorvir sodium), ALG-020572, and ALG-055009, are in early to mid-stage clinical trials (Phase Ib, Phase I, Phase 1a/1b, Phase 2), and there is no guarantee that they will demonstrate sufficient efficacy or safety, or ultimately receive marketing authorization.
-
Competition: Aligos Therapeutics operates in highly competitive therapeutic areas, including chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Numerous other pharmaceutical and biotechnology companies are actively developing or marketing competing therapies for these conditions. Aligos' drug candidates, particularly ALG-055009 for NASH, are positioned in a "competitively challenged" landscape. The company's ability to differentiate its products and secure market share against existing and emerging treatments is a significant risk.
AI Analysis | Feedback
AI Analysis | Feedback
Aligos Therapeutics (ALGS) focuses on developing novel therapeutics for viral and liver diseases, with lead drug candidates targeting Chronic Hepatitis B (CHB) and Non-alcoholic Steatohepatitis (NASH). The addressable markets for these main products are substantial globally and in key regions.
Chronic Hepatitis B (CHB)
- The global chronic hepatitis B market was valued at approximately USD 2,709.4 million in 2023 and is projected to reach USD 3,379.3 million by 2034.
- The Chronic Hepatitis B therapeutics market across the seven major markets (7MM), which include the U.S., EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is forecast to grow from USD 1.5 billion in 2024 to USD 3.2 billion by 2034.
- In 2024, the U.S. alone represented the largest market for CHB within the 7MM, with sales of USD 710.11 million. The U.S. Hepatitis B Treatment Market is projected to grow from USD 1.00 billion in 2025 to USD 1.54 billion by 2033.
Non-alcoholic Steatohepatitis (NASH)
- The global NASH drugs market was valued at USD 5.7 billion in 2024, is projected to reach USD 7.7 billion in 2025, and is expected to grow significantly to USD 78.2 billion by 2035.
- Another estimate places the global non-alcoholic steatohepatitis treatment market size at USD 7.72 billion in 2024, with a projection to reach USD 33.80 billion by 2030. Similarly, the global non-alcoholic steatohepatitis treatment market size was calculated at USD 7.75 billion in 2024 and is projected to reach around USD 92.5 billion by 2034.
- North America dominated the global non-alcoholic steatohepatitis treatment market, accounting for a 79.12% share in 2024. The U.S. non-alcoholic steatohepatitis treatment market was valued at USD 4.56 billion in 2024 and is expected to reach USD 32.55 billion by 2032. In 2023, the U.S. NASH market was approximately USD 1,519 million.
AI Analysis | Feedback
- Milestone Payments from Existing Collaboration Agreements: Aligos Therapeutics stands to generate revenue through milestone payments from its existing license and collaboration agreements. Specifically, the company has an agreement with Merck for the discovery and development of oligonucleotide therapies for non-alcoholic steatohepatitis (NASH) and up to one additional cardiometabolic/fibrosis target. Under this collaboration, Aligos is eligible for development and commercialization milestones that could reach up to $458 million to $460 million, in addition to tiered royalties on net sales. Furthermore, its partnership with Xiamen Amoytop Biotech Co. for ALG-170675, a dual-mechanism antisense oligonucleotide for chronic hepatitis B (CHB), involves Amoytop funding development costs in China and advancing the candidate into IND-enabling studies, which could trigger additional milestone payments to Aligos.
- New Partnership for ALG-055009 (Obesity/MASH): Aligos is actively pursuing a partnership for its small molecule THR-β agonist, ALG-055009, which is being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Recent preclinical data demonstrating significant synergistic weight loss when ALG-055009 is combined with incretin therapies (like GLP-1s) has substantially enhanced its commercial appeal beyond MASH, potentially accelerating discussions for a lucrative out-licensing deal. Such a new collaboration could provide Aligos with upfront payments, development milestones, and future royalties, contributing significantly to its revenue growth. The company has expressed enthusiasm and is in "continued discussions with potential partners for obesity and MASH" for ALG-055009.
- Advancement and Potential Monetization of Chronic Hepatitis B (CHB) Pipeline: The progression of Aligos' lead CHB drug candidate, pevifoscorvir sodium (ALG-000184), is a crucial driver. The Phase 2 B-SUPREME study for pevifoscorvir sodium has completed planned enrollment for the HBeAg- cohort and is continuing enrollment for the HBeAg+ cohort, with interim analyses expected in the first and second half of 2026, and topline data anticipated in 2027. Positive clinical trial readouts are essential to attracting new partners or expanding existing collaborations for the CHB program, which could lead to further milestone payments or new licensing agreements. The company believes pevifoscorvir sodium may impact key aspects of HBV disease pathogenesis (replication, integration, and viral reservoir maintenance).
AI Analysis | Feedback
Share Issuance
- Aligos Therapeutics completed a public offering in June 2021, issuing 4,400,000 shares of common stock at $19.00 per share, generating gross proceeds of approximately $83.6 million.
- In March 2026, a registration statement was filed for the issuance of 519,783 shares of common stock under the 2020 Incentive Award Plan and 61,782 shares under the 2020 Employee Stock Purchase Plan.
- In January 2026, the company granted non-qualified stock options for an aggregate of 81,100 shares to newly hired employees as inducement grants.
Inbound Investments
- Aligos Therapeutics has raised a total of $225 million across four funding rounds.
- Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, which is expected to provide sufficient funding into the third quarter of 2026.
Capital Expenditures
- In the 12 months leading up to March 2026, capital expenditures amounted to -$437,000.
- The company invested $7K in capital expenditures in Q1 2023, primarily to fund long-term assets and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Aligos Therapeutics Earnings Notes | 12/16/2025 | |
| 9-Day Rally Sends Aligos Therapeutics Stock Up 62% | 11/27/2025 | |
| Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak | 11/26/2025 | |
| Aligos Therapeutics Stock Rockets 59% With 8-Day Winning Streak | 11/26/2025 | |
| Can Aligos Therapeutics Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 72.11 |
| Mkt Cap | 11.0 |
| Rev LTM | 772 |
| Op Inc LTM | -275 |
| FCF LTM | -150 |
| FCF 3Y Avg | -211 |
| CFO LTM | -146 |
| CFO 3Y Avg | -172 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.8% |
| Rev Chg 3Y Avg | 136.1% |
| Rev Chg Q | 71.2% |
| QoQ Delta Rev Chg LTM | 7.6% |
| Op Inc Chg LTM | -56.9% |
| Op Inc Chg 3Y Avg | -16.1% |
| Op Mgn LTM | -33.8% |
| Op Mgn 3Y Avg | -945.9% |
| QoQ Delta Op Mgn LTM | 1.9% |
| CFO/Rev LTM | -15.4% |
| CFO/Rev 3Y Avg | -598.1% |
| FCF/Rev LTM | -16.0% |
| FCF/Rev 3Y Avg | -908.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | 2 | 4 | 16 | 14 | 4 |
| Total | 2 | 4 | 16 | 14 | 4 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | -24 | -131 | -88 |
| Total | -24 | -131 | -88 |
| $ Mil | 2020 | 2019 |
|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | 265 | 147 |
| Total | 265 | 147 |
Price Behavior
| Market Price | $5.59 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/16/2020 | |
| Distance from 52W High | -58.0% | |
| 50 Days | 200 Days | |
| DMA Price | $5.38 | $7.31 |
| DMA Trend | down | down |
| Distance from DMA | 3.8% | -23.6% |
| 3M | 1YR | |
| Volatility | 84.2% | 82.9% |
| Downside Capture | 114.70 | 72.43 |
| Upside Capture | 30.45 | 19.00 |
| Correlation (SPY) | 26.2% | 20.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.24 | 0.61 | 1.35 | 1.62 | 1.27 | 1.86 |
| Up Beta | 4.98 | 1.78 | 1.89 | 2.80 | 2.73 | 1.73 |
| Down Beta | 1.13 | 1.79 | 2.02 | 2.35 | 1.97 | 2.42 |
| Up Capture | -198% | -102% | 5% | 14% | 5% | 138% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 17 | 28 | 59 | 127 | 353 |
| Down Capture | 249% | 77% | 176% | 157% | 100% | 111% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 12 | 23 | 32 | 64 | 122 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | -30.6% | 82.8% | -0.08 | - |
| Sector ETF (XLV) | 28.7% | 15.5% | 1.42 | 18.5% |
| Equity (SPY) | 23.3% | 12.8% | 1.36 | 20.1% |
| Gold (GLD) | 28.5% | 28.4% | 0.87 | 8.1% |
| Commodities (DBC) | 32.9% | 19.8% | 1.32 | -4.9% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 8.5% |
| Bitcoin (BTCUSD) | -43.7% | 43.0% | -1.21 | 19.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | -56.9% | 99.6% | -0.37 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | 15.5% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | 25.0% |
| Gold (GLD) | 18.6% | 18.6% | 0.81 | 1.4% |
| Commodities (DBC) | 8.2% | 19.6% | 0.31 | 4.0% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 14.4% |
| Bitcoin (BTCUSD) | 9.0% | 53.0% | 0.36 | 19.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | -34.4% | 99.8% | -0.26 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 15.1% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 23.7% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 1.0% |
| Commodities (DBC) | 7.4% | 18.0% | 0.33 | 3.9% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 14.0% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 16.2% | ||
| 5/7/2026 | 6.8% | 10.9% | -17.7% |
| 3/5/2026 | -2.9% | 10.3% | 16.2% |
| 11/6/2025 | -3.1% | -11.9% | 47.1% |
| 8/6/2025 | 1.1% | -4.9% | 41.0% |
| 5/6/2025 | -9.3% | 12.5% | 24.6% |
| 3/10/2025 | -19.6% | -11.6% | -61.0% |
| 11/6/2024 | 6.1% | 109.4% | 206.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 11 |
| # Negative | 12 | 11 | 11 |
| Median Positive | 5.7% | 10.3% | 21.8% |
| Median Negative | -3.0% | -11.6% | -17.7% |
| Max Positive | 21.9% | 109.4% | 206.6% |
| Max Negative | -19.6% | -17.6% | -61.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 16.2% | ||
| 5/7/2026 | 6.8% | 10.9% | -17.7% |
| 3/5/2026 | -2.9% | 10.3% | 16.2% |
| 11/6/2025 | -3.1% | -11.9% | 47.1% |
| 8/6/2025 | 1.1% | -4.9% | 41.0% |
| 5/6/2025 | -9.3% | 12.5% | 24.6% |
| 3/10/2025 | -19.6% | -11.6% | -61.0% |
| 11/6/2024 | 6.1% | 109.4% | 206.6% |
| 8/6/2024 | 21.9% | 20.6% | 6.8% |
| 5/7/2024 | -0.9% | -12.5% | -26.8% |
| 3/12/2024 | 0.0% | 7.1% | 21.8% |
| 11/2/2023 | 1.4% | 2.7% | -9.3% |
| 8/3/2023 | -0.6% | 9.0% | -2.2% |
| 5/4/2023 | -8.8% | -17.6% | -16.2% |
| 3/9/2023 | -2.9% | -2.9% | -34.4% |
| 11/2/2022 | -1.9% | -16.5% | -10.3% |
| 8/4/2022 | 7.9% | 0.7% | -12.2% |
| 5/4/2022 | -11.3% | -12.1% | 5.6% |
| 3/10/2022 | 5.7% | 12.2% | -26.5% |
| 11/4/2021 | 5.5% | 5.0% | -20.5% |
| 8/5/2021 | -2.5% | -3.1% | 5.1% |
| 5/10/2021 | 5.6% | -10.1% | 19.4% |
| 3/23/2021 | -9.8% | -1.9% | 22.3% |
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 11 |
| # Negative | 12 | 11 | 11 |
| Median Positive | 5.7% | 10.3% | 21.8% |
| Median Negative | -3.0% | -11.6% | -17.7% |
| Max Positive | 21.9% | 109.4% | 206.6% |
| Max Negative | -19.6% | -17.6% | -61.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/23/2021 | 10-K |
| 09/30/2020 | 11/25/2020 | 10-Q |
| 06/30/2020 | 10/19/2020 | 424B4 |
Recent Forward Guidance
Updated 8/7/2026Latest: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Milestone Payment | 3.00 Mil | ||||||
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 Cash Runway | |||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.